Peptides having reduced toxicity that stimulate cholesterol efflux
AssigneeThe Regents of the University of California
InventorsJohn K. Bielicki, Jan Johansson, Waleed Danho
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of California
InventorsJohn K. Bielicki, Jan Johansson, Waleed Danho
Estimating the term…
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
-22. (canceled)
A method for mediating cholesterol efflux in a human patient diagnosed as having dementia or at risk of having dementia, and having at least one ApoE4 allele, said method comprising administering to said human a polypeptide having cholesterol efflux activity, wherein the polypeptide comprises an amino acid sequence that is an amphipathic α-helix that has a non-polar surface and a polar surface, wherein the polar surface comprises charged and uncharged amino acid residues at the lipid-water interface, wherein the amino acid sequence:
Dependencies are inferred from the claim text.